Review



dcodetm dextramer® specificity  (Avidity Science LLC)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Avidity Science LLC dcodetm dextramer® specificity
    ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the <t>Dextramer</t> assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.
    Dcodetm Dextramer® Specificity, supplied by Avidity Science LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcodetm+dextramer%C2%AE+specificity/med_rxiv__2023__04__13__23288227-366-23-41?v=Avidity+Science+LLC
    Average 90 stars, based on 1 article reviews
    dcodetm dextramer® specificity - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Human SARS-CoV-2 challenge resolves local and systemic response dynamics"

    Article Title: Human SARS-CoV-2 challenge resolves local and systemic response dynamics

    Journal: medRxiv

    doi: 10.1101/2023.04.13.23288227

    ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the Dextramer assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.
    Figure Legend Snippet: ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the Dextramer assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.

    Techniques Used: Infection

    ( a ) Gating strategy used to enrich SARS-CoV-2 antigen specific T cells via MACSQuant Tyto cell sorting. Cells were sequentially stained with a multi-allele panel of dCODE dextramer-PE complexes, with the addition of anti-human CD3-APC and CD14-FITC FACS antibodies as references to help us identify T cell specific binding. Debris and cell aggregates were gated out first using BSB-H (backscatter blue laser-height) SSC-H (side scatter-height). From the cells, DAPI+ dead cells were excluded. T cells (CD3+) and monocytes (CD14+) were then gated for (CD3+ and\or CD14+ population) and the sort gate defined from this population as all PE-dCODE Dextramer® positive cells. This lenient sorting strategy was decided upon in order to collect enough cells for 10X 5’ single cell analysis downstream and to ensure we were capturing all SARS-CoV-2 antigen specific cells. Any non-specific binding (e.g. to monocytes) and background noise could then be removed computationally. ( b ) Calculated quality control metrics for PE-dCODE Dextramer® positive sequenced cells showing gene reads per cell per sample. ( c ) Proportions of activated T cells bound to Dextramers loaded with selected SARS-CoV-2 antigens. The total amount of bound cells to each Dextramer is shown, color-coded by predicted cell state. If barcodes from several Dextramers were detected to be bound to the same cell, we only selected the Dextramer with the highest signal as bound. As a control to separate background and real binding, cells are separated based on the HLA haplotype compatibility with the tested Dextramer. Only Dextramers with at least 10 HLA matched bound cells are shown. FDR corrected p values were determined by a Fisher-exact test comparing the proportion of HLA matched activated T cells in the Dextramer bound cells to the proportion of unbound HLA matched activated T cells. N represents the number of cells in each bar. The right-most bar represents the overall distribution of cell types across all Dextramer experiments.
    Figure Legend Snippet: ( a ) Gating strategy used to enrich SARS-CoV-2 antigen specific T cells via MACSQuant Tyto cell sorting. Cells were sequentially stained with a multi-allele panel of dCODE dextramer-PE complexes, with the addition of anti-human CD3-APC and CD14-FITC FACS antibodies as references to help us identify T cell specific binding. Debris and cell aggregates were gated out first using BSB-H (backscatter blue laser-height) SSC-H (side scatter-height). From the cells, DAPI+ dead cells were excluded. T cells (CD3+) and monocytes (CD14+) were then gated for (CD3+ and\or CD14+ population) and the sort gate defined from this population as all PE-dCODE Dextramer® positive cells. This lenient sorting strategy was decided upon in order to collect enough cells for 10X 5’ single cell analysis downstream and to ensure we were capturing all SARS-CoV-2 antigen specific cells. Any non-specific binding (e.g. to monocytes) and background noise could then be removed computationally. ( b ) Calculated quality control metrics for PE-dCODE Dextramer® positive sequenced cells showing gene reads per cell per sample. ( c ) Proportions of activated T cells bound to Dextramers loaded with selected SARS-CoV-2 antigens. The total amount of bound cells to each Dextramer is shown, color-coded by predicted cell state. If barcodes from several Dextramers were detected to be bound to the same cell, we only selected the Dextramer with the highest signal as bound. As a control to separate background and real binding, cells are separated based on the HLA haplotype compatibility with the tested Dextramer. Only Dextramers with at least 10 HLA matched bound cells are shown. FDR corrected p values were determined by a Fisher-exact test comparing the proportion of HLA matched activated T cells in the Dextramer bound cells to the proportion of unbound HLA matched activated T cells. N represents the number of cells in each bar. The right-most bar represents the overall distribution of cell types across all Dextramer experiments.

    Techniques Used: FACS, Staining, Binding Assay, Single-cell Analysis, Control



    Similar Products

    dcodetm dextramer® specificity  (Avidity Science LLC)
    90
    Avidity Science LLC dcodetm dextramer® specificity
    ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the <t>Dextramer</t> assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.
    Dcodetm Dextramer® Specificity, supplied by Avidity Science LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dcodetm+dextramer%C2%AE+specificity/med_rxiv__2023__04__13__23288227-366-23-41?v=Avidity+Science+LLC
    Average 90 stars, based on 1 article reviews
    dcodetm dextramer® specificity - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the Dextramer assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.

    Journal: medRxiv

    Article Title: Human SARS-CoV-2 challenge resolves local and systemic response dynamics

    doi: 10.1101/2023.04.13.23288227

    Figure Lengend Snippet: ( a ) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. ( b ) Dotplot as in (a), but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample. ( c ) Dotplot as in (a), but showing nasopharyngeal epithelial cells. (d) UMAP of all CD8+ T cells from the Dextramer assay, with cell types predicted by Celltypist model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by HLA compatibility.

    Article Snippet: To help avoid aggregates, each individual dextramer reagent was first microcentrifuge at full speed for 5 mins before adding 2 μL from each dCODETM Dextramer® specificity to a low-bind nucleus free 1.5 eppendorf tube (Eppendorf, 30108051) containing 8.8 μl 100μM d-Biotin (Avidity science, BIO200) (0.2 ul d-Biotin per number of dCODETM Dextramer® specificity i.e. 44).The dCODETM Dextramer® master mix was mixed by gently pipetting before the total volume (96.8 μl) was added to the resuspended cells.

    Techniques: Infection

    ( a ) Gating strategy used to enrich SARS-CoV-2 antigen specific T cells via MACSQuant Tyto cell sorting. Cells were sequentially stained with a multi-allele panel of dCODE dextramer-PE complexes, with the addition of anti-human CD3-APC and CD14-FITC FACS antibodies as references to help us identify T cell specific binding. Debris and cell aggregates were gated out first using BSB-H (backscatter blue laser-height) SSC-H (side scatter-height). From the cells, DAPI+ dead cells were excluded. T cells (CD3+) and monocytes (CD14+) were then gated for (CD3+ and\or CD14+ population) and the sort gate defined from this population as all PE-dCODE Dextramer® positive cells. This lenient sorting strategy was decided upon in order to collect enough cells for 10X 5’ single cell analysis downstream and to ensure we were capturing all SARS-CoV-2 antigen specific cells. Any non-specific binding (e.g. to monocytes) and background noise could then be removed computationally. ( b ) Calculated quality control metrics for PE-dCODE Dextramer® positive sequenced cells showing gene reads per cell per sample. ( c ) Proportions of activated T cells bound to Dextramers loaded with selected SARS-CoV-2 antigens. The total amount of bound cells to each Dextramer is shown, color-coded by predicted cell state. If barcodes from several Dextramers were detected to be bound to the same cell, we only selected the Dextramer with the highest signal as bound. As a control to separate background and real binding, cells are separated based on the HLA haplotype compatibility with the tested Dextramer. Only Dextramers with at least 10 HLA matched bound cells are shown. FDR corrected p values were determined by a Fisher-exact test comparing the proportion of HLA matched activated T cells in the Dextramer bound cells to the proportion of unbound HLA matched activated T cells. N represents the number of cells in each bar. The right-most bar represents the overall distribution of cell types across all Dextramer experiments.

    Journal: medRxiv

    Article Title: Human SARS-CoV-2 challenge resolves local and systemic response dynamics

    doi: 10.1101/2023.04.13.23288227

    Figure Lengend Snippet: ( a ) Gating strategy used to enrich SARS-CoV-2 antigen specific T cells via MACSQuant Tyto cell sorting. Cells were sequentially stained with a multi-allele panel of dCODE dextramer-PE complexes, with the addition of anti-human CD3-APC and CD14-FITC FACS antibodies as references to help us identify T cell specific binding. Debris and cell aggregates were gated out first using BSB-H (backscatter blue laser-height) SSC-H (side scatter-height). From the cells, DAPI+ dead cells were excluded. T cells (CD3+) and monocytes (CD14+) were then gated for (CD3+ and\or CD14+ population) and the sort gate defined from this population as all PE-dCODE Dextramer® positive cells. This lenient sorting strategy was decided upon in order to collect enough cells for 10X 5’ single cell analysis downstream and to ensure we were capturing all SARS-CoV-2 antigen specific cells. Any non-specific binding (e.g. to monocytes) and background noise could then be removed computationally. ( b ) Calculated quality control metrics for PE-dCODE Dextramer® positive sequenced cells showing gene reads per cell per sample. ( c ) Proportions of activated T cells bound to Dextramers loaded with selected SARS-CoV-2 antigens. The total amount of bound cells to each Dextramer is shown, color-coded by predicted cell state. If barcodes from several Dextramers were detected to be bound to the same cell, we only selected the Dextramer with the highest signal as bound. As a control to separate background and real binding, cells are separated based on the HLA haplotype compatibility with the tested Dextramer. Only Dextramers with at least 10 HLA matched bound cells are shown. FDR corrected p values were determined by a Fisher-exact test comparing the proportion of HLA matched activated T cells in the Dextramer bound cells to the proportion of unbound HLA matched activated T cells. N represents the number of cells in each bar. The right-most bar represents the overall distribution of cell types across all Dextramer experiments.

    Article Snippet: To help avoid aggregates, each individual dextramer reagent was first microcentrifuge at full speed for 5 mins before adding 2 μL from each dCODETM Dextramer® specificity to a low-bind nucleus free 1.5 eppendorf tube (Eppendorf, 30108051) containing 8.8 μl 100μM d-Biotin (Avidity science, BIO200) (0.2 ul d-Biotin per number of dCODETM Dextramer® specificity i.e. 44).The dCODETM Dextramer® master mix was mixed by gently pipetting before the total volume (96.8 μl) was added to the resuspended cells.

    Techniques: FACS, Staining, Binding Assay, Single-cell Analysis, Control